SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back


Speakers
Mercedes E. Gonzalez, MD
Medical Director, Pediatric Dermatology of Miami
Clinical Assistant Professor, Dr. Phillip Frost Department of Dermatology
University of Miami Miller School of Medicine
Clinical Assistant Professor
Herbert Wertheim College of Medicine, Florida International University
Miami, FL

Linda F. Stein Gold, MD, FAAD
Director of Dermatology Clinical Research
Division Head of Dermatology
Henry Ford Health System
West Bloomfield, MI

Moderator
Brad P. Glick, DO, MPH, FAAD, FAOCD
Program Director, Dermatology Residency
Larkin Community Hospital Palm Springs
Deputy Chair, Individual Giving Committee, AAD
Vice President, Florida Society for Dermatology and Dermatologic Surgery
Clinical Assistant Professor of Dermatology
Herbert Wertheim College of Medicine
Miami, FL

Medical Writer
Wendy Gloffke, PhD
Medical Writing & Communications
Scranton, PA

Title
: Addressing Type 2 Inflammation in Atopic Dermatitis: Individualizing Care Across Populations
Activity/Course #:
: RealCME2492
Cost:
: Free
Release/Start Date:
: May 01 2019
Expiration Date:
: Jul 01 2020
Topics:
: Dermatology
Target Audience:
: Dermatologists, Primary Care Physicians, Pediatricians, Nurse Practitioners, Physician Assistants, Managed Care, and other clinicians managing patients with Atopic Dermatitis
Format:
: RealCME
Estimated Time To Complete CME Activity:
: 1.0 Hour
Credit(s):
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.75 pharmacology hour(s)
Hardware/Software Requirements:
Program Summary

Atopic dermatitis (AD) is a multifactorial, chronic inflammatory and heterogeneous disorder that affects up to 20% of children and up to 3% of adults. The disease is characterized by intense itching, secondary skin infections, and recurrent eczematous lesions, and poses a significant burden on healthcare resources and patients' quality of life.

There is a wide variation in knowledge, competence and practice patterns among clinicians regarding the assessment and management of atopic dermatitis and its comorbidities. To ideally address the variation in individual knowledge, competence and practice patterns, the proposed curriculum is designed to provide learners with a serial learning curriculum with personalized learner pathways. This initial self-assessment activity will discuss the pathogenesis of AD, particularly the role of the Th2 pathway to increase ability to recognize the clinical presentations and differential diagnosis of AD. It will provide information on the current research and trial data supporting treatment for individualized treatment of AD with consideration to the full spectrum of treatment options and disease severity, recognize the risks and safety profiles for effective AD management, and integrating the recognition of comorbidities into management.

After completing this activity, learners will be invited to participate in a subset of subsequent brief, single-issue focused “micro-activities” that best address their learning gaps, covering topics that they have not yet mastered, as demonstrated in this self-assessment activity.


Learning Objectives
After participating in the proposed educational activities, clinicians should be better able to:

1. Describe the pathogenesis of AD, particularly the role of the Th2 pathway
2. Demonstrate increased ability to recognize the clinical presentations and differential diagnosis of AD
3. Discuss the current research and trial data supporting treatment options for AD
4. Individualize AD treatment with consideration to the full spectrum of treatment options and disease severity
5. Recognize the risks and safety profiles of current treatments for effective AD management
6. Integrate the recognition of comorbidities into the management AD

Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Creditô. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education which includes 0.75 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Speakers
Dr. Gonzalez is a member of the Advisory Board at Pfizer, Regeneron and Verrica Pharmaceuticals. She is also a speaker and principal investigator for Pfizer, AbbVie, and Regeneron; and an independent contractor for Unilever and Verrica Pharmaceuticals.

Dr. Stein Gold is a consultant for Pfizer, Dermavant and Sanofi Regeneron; and an advisor for Leo Pharma, Dermira, Pfizer and Sanofi Genzyme. She is also a speaker for Leo Pharma, Pfizer, Sanofi Regeneron and Sanofi Genzyme; and a Principal Investigator for Abbott, Leo Pharma, Dermira, Abbvie, Incyte and Pfizer.

Moderator
Dr. Glick serves on the speakerís bureau for SunPharma, Abbvie, Janssen, Celgene, Lilly, Novartis Pharmaceuticals Corporation, Ortho Dermatologics, Sanofi Regeneron, Dermira, Pfizer, Dermavant, and Sanofi Genzyme. He is also an advisor for Dermavant, Pfizer, Sanofi Genzyme, Dermira, Novartis, Lilly, SunPharma, Celgene and Abbvie; and an investigator for Abbvie, Celgene, Dermavant and ChemoCentryx.

Activity Planning Committe
Michelle Frisch has no real or apparent conflicts of interest to report.

Gregg Sherman, MD has no real or apparent conflicts of interest to report.

Sandy Bihlmeyer, M.Ed. has no real or apparent conflicts of interest to report.

Daniela Hiedra has no real or apparent conflicts of interest to report.

Wendy Gloffke, Medical Writer has no real or apparent conflicts of interest to report.
Commercial Support
This educational activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals